VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Detail

Varivax
Vaccine Information
  • Vaccine Name: Varivax
  • Target Pathogen: Varicella-zoster virus
  • Target Disease: chickenpox / shingles
  • Product Name: Varicella Virus Vaccine Live
  • Tradename: Varivax
  • Manufacturer: Merck & Co., Inc.
  • Vaccine Ontology ID: VO_0000119
  • CDC CVX code: 21
  • Type: Live, attenuated vaccine
  • Status: Licensed
  • Location Licensed: USA (License #0002)
  • Host Species for Licensed Use: Human
  • Antigen: OkaIMerck strain of live, attenuated varicella vlrus.
  • Preparation: The OkaIMerck strain of live, attenuated varicella vlrus was initially obtained from a child with wild-type varicella, then introduced into human embryonic lung cell'cultures, adapted to and propagated in embryonic guinea pig cell cultures and finally propagated in human diploid cell cultures (WI-38). This live, attenuated varicella vaccine is a lyophllized preparation containing sucrose, phosphate, glutamate, processed gelatin, and urea as stabilizers. The product contains no preservative (FDA: Varivax).
  • Immunization Route: Intradermal injection (i.d.)
  • Storage: DO NOT FREEZE, store at 2 to 8°C or colder (36 to 46°F or colder).
  • Approved Age for Licensed Use: 1 year and older
  • Contraindication: A history of hypersensitivity to any component of the vaccine, including gelatin (FDA: Varivax).
  • Description: Indication: For active immunization of persons 12 months of age and older.
Host Response

Human Response

  • Immune Response: Clinical trials with several formulations of VARIVAX containing the attenuated virus ranging from 1000 to 50,000 PFU per dose, have demonstrated that VARIVAX induces detectable immune responses and is generally well tolerated in healthy individuals ranging from 12 months to 55 years of age. VARIVAX was also found to induce cell-mediated immune responses in vaccinees (FDA: Varivax).
  • Side Effects: Side effects of vaccination were mostly injection site redness and pain.
  • Efficacy: The majority of subjects who received the vaccine and were exposed to wild-type virus were either completely protected from chickenpox or developed a milder form of the disease. Clinical studies have demonstrated continued protection up to 10 years after vaccination. Also, a boost in antibody levels has been observed in vaccinees following exposure to wild-type varicella as well as following a second dose of the vaccine (FDA: Varivax).
References
FDA: Varivax: FDA: Varivax vaccine information [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm094073.htm]